IDEAYA Biosciences, Inc. (IDYA) Q2 2020 Earnings Results

IDEAYA Biosciences I Misses on EPS, Stock Down 1.71%

This earnings report indicates that IDEAYA Biosciences I is facing challenges, particularly in terms of EPS performance. The stock reacted negatively, declining by 1.71%, likely due to the disappointing EPS figure and lack of revenue data. Investors may be concerned about the company's future financial outlook without clear guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.59	N/A	-126.32%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious approach regarding future performance. They emphasized the importance of ongoing clinical development.

Management did not provide specific details on revenue expectations.

The focus remains on advancing clinical programs.

IDEAYA Biosciences I Misses on EPS, Stock Down 1.71%

Key numbers

Management commentary

IDEAYA Biosciences, Inc.

More earnings this week

IDEAYA Biosciences I Misses on EPS, Stock Down 1.71%

Key numbers

Management commentary